Rewriting Sickle Cell Disease: The Promise of In Vivo Gene Editing and the Global Equity Challenge

September 13, 2026

Current Opinion in Hematology USA

Overview

The quest to cure sickle cell disease (SCD) hinges on establishing durable, healthy hematopoiesis without significant toxicity. While cutting-edge in vivo and prenatal hematopoietic stem cell (HSC) gene editing approaches hold immense promise, their success demands non-genotoxic delivery, robust maternal-fetal safety, and equitable global governance. Therapies like exagamglogene autotemcel (exa-cel), which reactivate fetal hemoglobin through BCL11A enhancer editing, exemplify this therapeutic revolution.

In Depth

Background: The Global Challenge of Sickle Cell Disease

Sickle cell disease (SCD) is a prevalent genetic blood disorder affecting millions worldwide, causing severe pain, organ damage, and premature death. Historically, treatments have largely been limited to symptomatic care and bone marrow transplantation, with the latter requiring a matched donor and carrying inherent risks of complications. Gene therapy has generated immense hope for a curative approach to SCD, with successes like exagamglogene autotemcel (exa-cel) marking significant progress in the field. Nevertheless, ensuring equitable access to these advanced therapies and preventing the exacerbation of global health disparities through robust governance models remains a critical international challenge.

Advances in Gene Editing: Promise and Hurdles

The treatment of SCD is confronting a pivotal challenge: establishing durable and healthy hematopoiesis without incurring unacceptable toxicity. While in vivo and prenatal hematopoietic stem cell (HSC) gene editing are emerging as highly promising therapeutic pathways for SCD, their successful realization critically depends on the development of non-genotoxic delivery systems, stringent evidence for maternal and fetal safety, and the establishment of equitable governance models. Historically, gene therapy for SCD predominantly involved ex vivo approaches, where a patient’s own HSCs are harvested, genetically edited outside the body, and then reinfused. However, in vivo editing technologies aim to directly modify HSCs within the body, potentially reducing the burden of pre-transplant conditioning and improving treatment accessibility. Notably, approaches like exa-cel, which utilizes CRISPR technology to edit the erythroid-specific enhancer of the BCL11A gene to reactivate fetal hemoglobin (HbF) production, have achieved clinical success and garnered regulatory approval. Increased HbF prevents sickling, thereby ameliorating SCD symptoms. Prenatal editing, while offering the ultimate intervention before disease onset, demands extremely rigorous safety evidence for both mother and fetus, alongside broad ethical and societal consensus.

Strategic Outlook: Ensuring Equitable Access and Long-term Safety

In vivo and prenatal HSC gene editing technologies will be integral in shaping the future of SCD treatment. Research and development will concentrate on creating safer and more efficient gene delivery systems (e.g., non-viral vectors), minimizing off-target effects, and confirming long-term safety and efficacy through extended follow-up studies. Furthermore, there is an urgent need to establish policy and economic frameworks that can deliver these innovative therapies not only to high-income countries but also to patients in low- and middle-income countries where SCD is endemic. Equitable access and ethical considerations will be key to the success of next-generation SCD treatments.

Source: https://www.ovid.com/10.1097/MOH.0000000000000955

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.